2019-09-03T16:15:06-05:00 2018-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2018-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2175 K Street NW No 400 Washington DC 20037 Amy Finan Chief Executive Officer 2028428610 2019-09-03 1 Jie Chen CPA P01049760 7038930300 2019-09-03 174.70.27.74 2019-09-03 17:11:52 ED P ECEE9D0F9FA27E6B6A8A3848667CA5FDB2C7423A 63C1C0B9F93C8B40CBCDC4B3DDBC3363D21A7384 2018 2019-02-21 02:37:17Z Amy Finan 2175 K Street NW No 400 Washington DC 20037 10508799 0 X www.sabin.org X 1994 MD To make vaccines more accessible, enable innovation and expand immunization. 7 6 39 5 0 14760 8075830 10410527 1225 0 27008 50519 15222 0 8119285 10461046 3260072 1858021 0 0 3832495 3723726 0 0 203576 3474104 4830598 10566671 10412345 -2447386 48701 15194291 16463026 2094947 3362329 13099344 13100697 X To make vaccines more accessible, enable innovation and expand immunization across the globe. 0 0 5146833 1713826 Vaccine Access and Uptake: Despite scientific advances and international support, 1.5 million people still die each year from diseases that could have been prevented by routine immunization. Sabin works with key decision makers and immunization experts at the country and global level to build resilient, sustainable national immunization programs to reach every child.It is countries' responsibility to provide effective and quality immunization for all people. Sabin partners with low- and middle-income countries to strengthen policy, secure financing and build political will for immunization. Sabin seeks to help countries establish long-term immunization financing and policy solutions that strengthen and protect immunization systems for generations to come.Sabin is an adviser, a convener and a catalyst of systemic change, bringing together researchers, national government officials and immunization specialists at all levels to support the introduction and expansion of new and under-utilized vaccines. In order to make informed decisions about vaccine introduction and implementation, countries require high-quality information and evidence. Sabin supports surveillance programs and conducts research to generate essential epidemiological data for well-designed and efficiently implemented immunization programs. By establishing and sharing best practices, we help countries evaluate and streamline vaccine introduction and scale-up.Collaboration across continents and sectors is critical to extend the benefits of immunization around the globe. Through our international scientific meetings, Sabin fosters dialogue between global health leaders, researchers and implementers to unify global efforts to accelerate access to new and under-utilized vaccines. 3061556 45750 Vaccine Knowledge & Innovation: The immunization landscape is constantly evolving. Immunization professionals are faced with the challenge of staying up-to-date on new vaccines, changing policies and recommendations, and developments in vaccine science, while the general public is inundated with information, making it difficult to discern truth from fiction.Sabin drives meaningful, well-informed conversations on emerging and established issues across the field of immunization and provides training and education on the latest in vaccine science and policy to immunization professionals, policymakers and journalists, among others.Sabin connects immunization professionals with the resources they need to overcome barriers to vaccination and improve vaccine uptake and coverage in their countries. Our scientific meetings, trainings and workshops provide professionals with the skills and tools to strengthen their countries' vaccine research capabilities, foster vaccination program resiliency and implement successful immunization campaigns.Sabin works to shape the vaccine conversation by amplifying reliable information on vaccines. We serve as a leading voice on critical issues in global immunization, including vaccine confidence, vaccine safety and global health innovation. We also work to drive more effective, accurate media coverage on vaccines by equipping journalists with the latest information on disease burden and immunization. 448740 98445 Research & Development: Sabin supports innovative technologies and approaches in vaccine research and development. For more than a decade, Sabin has collaborated with organizations around the world conducting research to develop new, low-cost vaccines for diseases impacting the world's most neglected populations. Focusing on infectious and emerging diseases that have high human impact but may lack traditional market incentives, Sabin is committed to supporting research to identify innovative solutions that will improve the lives of millions through immunization. 8657129 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 34 0 1 39 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL X The Organization 2028428610 2175 K Street NW No 400 Washington DC 20037 Finan Amy Officer - CEO; Ex Officio Trustee 40.00 X X 362202 0 21909 Holman Wendy Trustee 2.00 X 0 0 0 Hoos Axel Trustee, Chairman 2.00 X X 0 0 0 Marine Michael Trustee, Secretary 2.00 X X 0 0 0 Rabinovich Regina Trustee 2.00 X 0 0 0 Russell Philip Trustee 2.00 X 0 0 0 Thoren Peter Trustee, Vice Chairman 2.00 X X 0 0 0 Kelley Kenneth Trustee 2.00 X 0 0 0 Davis Brian Officer - COO 40.00 X 240580 0 33194 Gellin Bruce Officer - President, Global Immunization 40.00 X 306674 0 19291 Garrett Denise Vice President, Typhoid Program 40.00 X 216067 0 24529 Hayward Tara Vice President, Resource Development & Policy 40.00 X 163507 0 21874 Woodin Mary Beth Vice President, Communications 40.00 X 135722 0 17804 Daniels Janet Director, Accounting 40.00 X 129125 0 20341 Bianchi Maria Director, Administration 40.00 X 113250 0 13238 1667127 0 172180 11 0 1 0 Dalberg Consulting US LLC 99 Madison Ave Floor 17 New York NY 10016 Landscape analysis Flu program. 256807 The Aspen Institute 2300 N Street NW Washington DC 20037 Convene stakeholders for Flu program. 228920 Cult Health 261 Fifth Avenue Suite 1002 New York NY 10016 Promotion of Flu program. 177709 Home Front Communications LLC 1201 New York Ave NW Suite 900 Washington DC 20005 Communication strategy - Flu 174740 IDEO LP 150 Forest Avenue Palo Alto CA 94301 Support Sabin at Aspen Convening. 138408 6 267921 10142606 10410527 50519 50519 47753 47753 0 10461046 0 0 50519 X 350612 350612 1507409 1507409 983848 761067 174170 48611 2272942 1758260 402378 112304 70221 49850 17399 2972 192783 123800 60741 8242 203932 154397 38829 10706 43989 43989 16298 16298 1895848 1860059 33987 1802 144186 139530 4656 113315 56855 53098 3362 67882 25242 39865 2775 512654 512654 430917 424264 3861 2792 1111401 1103459 6432 1510 112 73 39 373139 252600 120539 43726 43726 Dues/subscriptions 34549 21116 6188 7245 Recruitment 22756 16537 5024 1195 Miscellaneous 19410 7594 11756 60 Books & publications 416 416 10412345 8657129 1551640 203576 2192495 1832931 8587760 10611306 761908 393095 18156 8150 101638 116160 1521946 501132 776946 1020814 288872 268217 2464953 2212353 1563 0 15194291 16463026 592250 1424511 4100 5969 1498597 1931849 2094947 3362329 X 2029399 1774230 11069945 11326467 13099344 13100697 15194291 16463026 X 48701 20499 -67847 X X 0 1 X 1 0 X 18983738 17896741 14719648 8075830 10410527 70086484 18983738 17896741 14719648 8075830 10410527 70086484 34001718 36084766 28526 23756 27774 27008 98272 205336 31650 15222 46872 70338692 55750 0.51300 0.52900 X 59 59 10390042 10390101 669505 167376 0 0 1000000 1000000 678334 669505 3347839 5021759 5538 4263 980 59 10840 250000 250000 169584 167376 836960 1255440 1897 784 2681 1192938 180890 1012048 329008 320242 8766 1020814 Deferred rent 1628579 Deferred compensation liability 297301 Security deposit 5969 1931849 X 10604899 20499 75601 96100 10508799 -47753 -47753 10461046 10390101 75601 600 76201 10313900 98445 98445 10412345 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. Part XI, Line 4b - Other Adjustments: Rental Expense -47,753. Part XII, Line 2d - Other Adjustments: Rental Expense 47,753. Refund of grant expense -47,153. Part XII, Line 4b - Other Adjustments: Grant expense 98,445. 1 South Asia 0 0 Grants to recipients located in region Typhoid study sites 1179674 South America - Argentina, Bolivia, Brazil, Chile, Columbia, Ecuador, 0 0 Grants to recipients located in region Dengue vaccine effectiveness study & clinical trial site 74515 East Asia and the Pacific 0 0 Grants to recipients located in region Typhoid study site 103525 Middle East and North Africa 0 0 Grants to recipients located in region Immunization advocacy 5500 Europe (Including Iceland & Greenland) 0 0 Grants to recipients located in region Health worker patient insights study, vaccine development program 144195 0 0 0 0 0 0 1507409 0 1507409 South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study sites 325048 EFT South America - Argentina, Bolivia, Brazil, Chile, Columbia, Ecuador, Dengue vaccine effectiveness study 74515 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study sites 548467 EFT South Asia - Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Typhoid study site 296762 EFT East Asia and the Pacific Typhoid study site 99705 EFT Europe (Including Iceland & Greenland) Health worker patient insights study 45750 EFT Europe (Including Iceland & Greenland) Vaccine development program 98445 EFT 7 Immunization advocacy Middle East and North Africa 2 5500 EFT Immunization advocacy South Asia 1 5412 EFT 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). 1 National Foundation for the Centers for Disease Control and Prevention 600 Peachtree Street NE Suite 1000 Atlanta GA 30308 582106707 501C3 73893 Typhoid study sites Pan American Health Organization 525 23rd Street NW Washington DC 20037 237072046 501C3 71569 Vaccine coverage study Stanford University PO Box 44253 San Francisco CA 94144 941156365 501C3 172363 Typhoid study sites Massachusetts General Hospital 55 Fruit Street GRJ 504 Boston MA 02114 041564655 501c3 32787 Typhoid study site 4 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X 0 0 0 0 0 0 0 0 0 Finan Amy Officer - CEO; Ex Officio Trustee 342202 0 20000 0 0 0 10164 0 11745 0 384111 0 0 0 Davis Brian Officer - COO 224080 0 16500 0 0 0 9301 0 23893 0 273774 0 0 0 Gellin Bruce Officer - President, Global Immuniza 306674 0 0 0 0 0 10959 0 8332 0 325965 0 0 0 Garrett Denise Vice President, Typhoid Program 216067 0 0 0 0 0 8751 0 15778 0 240596 0 0 0 Hayward Tara Vice President, Resource Development 163507 0 0 0 0 0 6237 0 15637 0 185381 0 0 0 Woodin Mary Beth Vice President, Communications 135722 0 0 0 0 0 2493 0 15311 0 153526 0 0 0 Form 990, Part VI, Section B, line 11b The Form 990 is prepared by an outside tax accounting firm based on independently audited financial statements. The Form 990 is then reviewed by the Director, Accounting and COO. Then the Form 990 is presented to the CEO and Finance and Audit Committee for their review and approval. Finally it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management, Board Chair and Governance Committee are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board, Executive Committe or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement and Form 990 (Sabin's website). Form 990, Part IX, line 11g Transcription/translation service: Program service expenses 33,168. Management and general expenses 0. Fundraising expenses 0. Total expenses 33,168. Consultants: Program service expenses 1,597,971. Management and general expenses 33,987. Fundraising expenses 1,802. Total expenses 1,633,760. Contractor: Program service expenses 228,920. Management and general expenses 0. Fundraising expenses 0. Total expenses 228,920. Form 990, Part XI, line 9: Return of contribution income -115,000. Refund of grant expense 47,153. Form 990, Part XII, Line 2c: The Organization has a Finance and Audit Committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.